SHANGHAI, China, December 1, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.<\/p>\n\n\n\n
This NCE application was submitted through Project Orbis, an initiative of the FDA\u2019s Oncology Center of Excellence (OCE) that provides a collaborative mechanism and framework among the FDA and regulatory partners in other countries and regions, for concurrent submission and review of oncology drugs. At present, seven other regulatory agencies have joined Project Orbis, including the TGA, Singapore Health Sciences Authority (HSA), Health Canada (HC), MHRA, etc.<\/p>\n\n\n\n
Project Orbis currently accepts applications for oncology indications. An application should generally qualify for FDA priority review, meaning that the drug must be intended to treat a serious disease and, if approved, would significantly improve the safety or efficacy of the treatment; furthermore, the drug should have a high impact and significant clinical benefits. Under the framework of Project Orbis, collaboration among international regulators may allow patients with cancer to receive earlier access to new treatments in other countries.<\/p>\n\n\n\n
Toripalimab for the treatment of NPC meets these application requirements and is the first domestic oncology drug to be included in Project Orbis. Junshi Biosciences will explore the possibility of fast marketing in these countries and regions where the pathway is applicable.<\/p>\n\n\n\n
NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common types of head and neck cancer. According to the World Health Organization, the number of newly diagnosed NPC cases in 2020 exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, while radiotherapy alone or in combination with chemotherapy are the main treatment options for localized cancers.<\/p>\n\n\n\n
This NCE application is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase III clinical study (NCT03581786), for the first-line treatment of NPC and the results from POLARIS-02, a multi-center, open-label, pivotal Phase II clinical study (NCT02915432), for second-line or more prior treatments for recurrent or metastatic NPC.<\/p>\n\n\n\n
The results of JUPITER-02, the first multinational multi-center, double-blind, randomized, placebo- controlled Phase III clinical study with immuno-oncology therapy for the treatment of NPC with the largest sample size, were published at the plenary session of the 2021 American Society of Clinical Oncology (ASCO) annual meeting (#LBA2), and in Nature Medicine<\/em> and the Journal of the American Medical Association<\/em> (JAMA<\/em>). The results showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy for the first-line treatment of metastatic or recurrent NPC significantly improved progression-free survival (PFS) and overall survival (OS), reduced the risk of disease progression or death by 48% and the risk of death by 37%, and demonstrated a manageable safety profile.<\/p>\n\n\n\n The POLARIS-02 results were published online in January 2021 in the Journal of Clinical Oncology<\/em>. The results showed that toripalimab demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate (ORR) of 20.5%, a median duration of response (DoR) of 12.8 months, and a median OS of 17.4 months with a manageable safety profile. So far, toripalimab has been approved for 6 indications in China, with 4 supplementary new drug applications (sNDA) currently under regulatory review. Internationally, it has been approved for 2 NPC indications in the US, and marketing approval applications for 2 indications in NPC and esophageal carcinoma are currently under regulatory review in the European Union and UK.<\/p>\n","protected":false},"excerpt":{"rendered":" Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n